Preclinical Testing

RoukenBio is a UK-based immunology-focused Collaborative Research Organisation (CRO)providing discovery to IND-enabling research services, alongside thedevelopment and manufacture of advanced cell-based tools. The company workswith global biotherapeutic innovators across inflammation, auto-immunity,immuno-oncology and oncology, supporting the generation of high-quality,reproducible data to inform therapeutic candidate selection and progressiontoward the clinic. RoukenBio operates through a collaborative research modeldesigned to integrate closely with customer programmes and scientific teams.

Immune Cell Assays

Building on deep immunology expertise, RoukenBio has developed a comprehensive suite of assay systems that model key immune cell functions and interactions in both health and disease.

With a strong emphasis on novel and emerging therapeutic modalities designed to modulate immune responses, RoukenBio’s immune cell assays support therapeutic development across immune‑oncology, autoimmunity, inflammation, allergy, and beyond.

They develop in vitro disease models that closely reflect underlying biology, supporting the evaluation of therapeutic candidates in relevant systems that generate robust data for reliable decision‑making.

T Cell Assays

RoukenBio’s in vitro Tcell assays provide detailed insights into T cell function, activation, and engineering. Supporting evaluation across multiple therapeutic modalities, their portfolio includes a wide range of assay set‑ups, like T cell activation, TDCC assays, T cell polarisation, Treg assays, Gamma-Delta T cell assays, T cell depletion, CAR-T cell engineering, and their highly utilised T cell exhaustion model.

Dendritic Cell Assays

RoukenBio provides a broad suite of dendritic cell (DC)assays to support immunology therapeutic development, utilising monocyte‑derivedDCs or DCs isolated from PBMCs where appropriate. Their assays generate comprehensive insights into DC activation, functionality, and their central role in immune responses.

NK Cell Assays

RoukenBio’s NK cell assay portfolio enables exploration of natural killer (NK) cell function and therapeutic potential, with models that reflect NK biology in immune surveillance and target-cell killing. Such in vitro platforms support assessment of NK cell activity and regulation across stress, infection, and malignancy contexts, and include formats such as NK cell–mediated ADCC (to evaluate antibody-driven target cell killing), NK cell activation and NK cell expansion.

Neutrophil Assays

RoukenBio’s in vitro neutrophil assays use primary neutrophils isolated from fresh whole blood to assess functional responses relevant to inflammatory, autoimmune, and oncology programmes. Their platforms enable detailed evaluation of neutrophil activation and effector mechanisms, including phagocytosis, degranulation, migration, and antibody‑dependent cellular cytotoxicity (ADCC).

Macrophage Assays

RoukenBio’s in vitro macrophage assays support drug development by enabling detailed assessment of macrophage function across health and disease. Using monocyte‑derived macrophages, they generate and polarise distinct macrophage populations to reflect disease‑relevant states, including pro‑ and anti‑inflammatory phenotypes.

Assay platforms support evaluation of macrophage polarisation, phagocytosis, antibody‑dependent cellular phagocytosis(ADCP), and interactions with other immune cells, providing insight into therapeutic mechanisms of action across oncology, autoimmune, and inflammatory programmes.

Tumour Cell Assays

RoukenBio’s tumour cell assays support oncology research and therapeutic development by providing access to a broad range of immortalised tumour cell lines and bespoke cell line engineering capabilities. Their platforms enable the generation or selection of disease‑relevant cancer cell targets that can be incorporated into immune cell and co‑culture assays to evaluate therapeutic activity in a biologically relevant context. These tailored tumour cell assay systems deliver insights into tumour biology and mechanisms of action, supporting the development and characterisation of novel cancer therapies.

Granulocyte Assays

RoukenBio’s granulocyte assays support immunological therapeutic development by enabling functional assessment of key granulocyte populations, including mast cells, eosinophils, and basophils. Drawing on deep expertise in granulocyte biology, their scientists design bespoke in vitro assays to evaluate how candidate therapeutics impact granulocyte viability, activation, and immune function. These platforms are particularly relevant to inflammatory, allergic, and immune‑mediated disease programmes.

Whole Blood Assays

RoukenBio’s whole blood assays enable physiologically relevant assessment of immune responses by preserving the full cellular and soluble complexity of human blood. Using fresh whole blood from a large, recallable donor pool with defined Fc receptor genotypes and HLA status, our platforms support phenotypic and functional analyses without the need for prior cell isolation. These assays are well suited for cytokine release, cytotoxicity, and immune activation studies, providing translational insights into therapeutic mechanisms of action and safety across a range of immunology and drug development programmes.